MMED Overview

MiniMed Group, Inc. is a medical technology company, which develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear.

Wall Street analysts forecast MMED stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MiniMed Group Inc revenue for the last quarter amounts to 752.00M USD, increased 10.26

MiniMed Group Inc. EPS for the last quarter amounts to -7.14 USD, decreased

MiniMed Group Inc (MMED) has 8000 emplpoyees as of May 11 2026.

Today MMED has the market capitalization of 3.25B USD.